Nexstim Plc (NXTMH: HEX, NXTMS: STO) (“Nexstim” or “Company”) invites the shareholders to the extraordinary general meeting of the company on the authorization of the board of directors to decide on share issues and the issue of Option rights and special rights to shares to decide The Extraordinary General Meeting will take place on Monday, 1 March 2021, from 1300 a.m. (EET) in the Nexstim headquarters, Elimäenkatu 9 B (inner courtyard), 4 Reception of people who have registered for the meeting starts at 12:30 p.m. (EET) As the risk of coronavirus infection remains significant, it is strongly recommended that all shareholders exercise their voting rights through a To be represented by the Company’s General Counsel.For more information and instructions on how to obtain authorization from a proxy, please visit the Company’s website at wwwnexstimcom / Investors / General Meetings / Individuals with flu symptoms who have been exposed to the coronavirus are particularly vulnerable to the virus or 14 days If you traveled outside Finland prior to the Annual General Meeting, please do not attend the Annual General Meeting in person. Due to the restrictions imposed by the Finnish authorities, the number of participants that can attend the event may be limited

3 Election of people to review the minutes and monitor the counting of votes

6 Authorization of the Board of Directors to decide on the issue of shares and on the issue of option rights and other special rights that are entitled to shares

61 Approved to be used for future financing needs of the company, to develop the equity structure, to minimize or reduce debt and possible mergers and acquisitions, and for other corporate purposes

The Board of Directors proposes that the Extraordinary General Meeting authorize the shareholder to decide on share issues as well as on issues of option rights and other special rights, which pursuant to Chapter 10 of the Companies Act as follows:

The shares issued as part of the approval are new or are owned by the company. On the basis of and within the scope of this authorization, the Board of Directors can also issue option rights or other special rights in accordance with Chapter 10 of the Company Law Decide on limited liability that supplement or replace the issue (s) of shares

A maximum of two hundred and twenty million (220000000) shares are issued, which corresponds to approximately 3335 percent of all shares in the company after the share issue, provided that new shares are issued, taking into account all registered shares of the company

When issuing new ordinary shares, shareholders have the right to subscribe for new shares in proportion to their existing holdings of shares in the company Shareholders cannot be subscribed In connection with shares that are not subscribed in such a rights issue, the Board of Directors is entitled, in the case of directed share issues or directed issues of option rights or special rights that are entitled to shares, to decide, in deviation from the shareholders’ subscription rights, that it there is a weighty financial reason for the company to do so. The stock and option rights or other special rights that are entitled to stocks can therefore be issued in one or more tranches

When issuing shares in the rights issue, the Board of Directors proposes that the provisional subscription price is EUR 0. 03 Taking this price level into account, the Company’s main shareholders, Ossi Haapaniemi, Kyösti Kakkonen and Leena Niemistö, together with affiliated companies / book entry accounts, have the controlled by everyone, as well as certain members of the board of directors and the company of the company.The management team has made preliminary commitments to the company regarding the subscription of new shares under such rights issue with certain conditions of up to approximately 48% of the authorized amount, which in total approximately 3 , 15 million EUR would correspond to

The Board of Directors has the discretion to determine the final subscription price and all conditions for the issue of shares and the granting of special rights to shares

The proposed authorization does not invalidate previous resolved and registered authorizations granted at the Annual General Meeting in relation to share issues and the issue of option rights and other special rights that are entitled to shares

The authorization is valid for one (1) year from the resolution of the extraordinary general meeting

The approval can be used for the company’s future funding needs, equity structure development, debt minimization or reduction, as well as possible mergers and acquisitions and other corporate purposes

62 The approval is to be used for the Board of Directors’ RSU plan and long-term incentive plans for the company’s management and staff

The Board of Directors proposes that the Extraordinary General Meeting authorize the Board of Directors to decide on share issues as well as options and other special rights entitled to shares in accordance with Chapter 10 of the Finnish Limited Liability Companies Proceed as follows:

The shares issued as part of the approval are new or are owned by the company. On the basis of and within the scope of this authorization, the Board of Directors can also issue option rights or other special rights in accordance with Chapter 10 of the Company Law Decide on limited liability that supplement or replace the issue (s) of shares

A maximum of nineteen million five hundred thousand (19th500000) shares are issued, which corresponds to approximately 25 percent of all shares in the company after the share issue, provided that new shares are issued, taking into account all registered shares of the company

The shares, option rights and / or other special rights that are entitled to shares can be issued in one or more tranches

The Board of Directors is authorized to regulate all the conditions for the issue of shares and the conditions for the granting of option rights and other special rights that are entitled to shares. The Board of Directors is authorized to specifically issue shares and issue special rights to resolve that entitle the shareholders to deviate from the subscription right if there is a serious financial reason for the company

The proposed authorization does not invalidate previous resolved and registered authorizations issued at the Annual General Meeting with respect to the issue of shares, the issue of option rights and other special rights that are entitled to shares

The authorization is valid for five (5) years from the resolution of the extraordinary general meeting

The approval can be used to implement the RSU plan for the board members and the long-term incentive plans for the management and staff of the company The approval can also be used for incentive agreements and the payment of the board of directors’ fees

63 Approved for use in the company’s future funding needs, to develop its equity structure, to minimize or reduce debt and possible mergers and acquisitions, and for other corporate purposes

The Board of Directors proposes that the Extraordinary General Meeting authorize the Board of Directors to decide on share issues as well as options and other special rights entitled to shares in accordance with Chapter 10 of the Finnish Limited Liability Companies Proceed as follows:

The shares issued as part of the approval are new or are owned by the company. On the basis of and within the scope of this authorization, the Board of Directors can also issue option rights or other special rights in accordance with Chapter 10 of the Company Law Decide on limited liability that supplement or replace the issue (s) of shares

A maximum of five million (5th000000) shares are issued, which corresponds to approximately 12 percent of all shares in the company after the share issue, provided that new shares are issued taking into account all registered shares of the company

The shares, option rights and / or other special rights that are entitled to shares can be issued in one or more tranches

The Board of Directors is authorized to regulate all the conditions for the issue of shares and the conditions for the granting of option rights and other special rights that are entitled to shares. The Board of Directors is authorized to specifically issue shares and issue special rights to resolve that entitle the company to deviate from the subscription right of the shareholders, provided that there is an important financial reason for the company. Such new shares can also be issued without payment, provided this is a particularly important financial reason for the company and the interests of all shareholders are taken into account / p>

The proposed authorization does not invalidate previous resolved and registered authorizations issued at the Annual General Meeting with respect to the issue of shares, the issue of option rights and other special rights that are entitled to shares

The authorization is valid for one (1) year from the resolution of the general meeting

The approval can be used in connection with future financing needs of the company (eG against payment of a fee to be paid in Nexstim shares for an investor who enters into a significant subscription obligation in connection with a possible share issue), development of the equity structure, minimization or Reduce debt as well as possible mergers and acquisitions and other corporate purposes

The proposals of the Board of Directors and other documents in Chapter 5, Section 21 of the Finnish Law on Limited Liability Companies (21) 62006/624 (as amended) and this notice are available on the Nexstim Plc website at www.nexstimcom / Investors / General Meetings / no later than 8 February 2021 (as printable PDF files) Such documents are also available at the Annual General Meeting March 2021 will be available on the above website

Every shareholder who February 2021, registered in the shareholders ‘register of the company managed by Euroclear Finland Ltd, has the right to attend the Extraordinary General Meeting.A shareholder whose shares are registered in his personal book entry account will be entered in the company’s shareholders’ register

A shareholder who would like to take part in the extraordinary general meeting must register no later than 24 Register for the Annual General Meeting February 2021 at 10 a.m. by giving prior notice of attendance. Such a notification can be made:

In connection with the registration, a shareholder must provide his name, his personal identification number or business number, his address, telephone number and the name of a possible assistant or representative.The personal data transmitted to Nexstim Plc will only be used in connection with the general meeting and processing appropriate registrations used

A holder of nominee registered shares has the right to participate in the extraordinary general meeting on the basis of these shares, on the basis of which he or she on the date of the extraordinary general meeting, iHe on 17 February 2021 would be entitled to be entered in the company’s register of shareholders held by Euroclear Finland Ltd. The right to participate in the general meeting also requires that the shareholder based on these shares have been registered by no later than February 2021 is entered in the preliminary shareholders’ register of Euroclear Finland Ltd at 10 a.m. For nominee registered shares, this is considered proper registration for the general meeting

A holder of nominee registered shares is advised to immediately request the necessary instructions from their custodian bank regarding entry in the Company’s register of shareholders, issuance of power of attorney and registration for the extraordinary general meeting of shareholders. The custodian bank’s account management organization must be a holder of Nominee registered shares wishing to attend the Extraordinary General Meeting should be entered in the company’s provisional register of shareholders by the above date at the latest

A shareholder with shares registered in Euroclear Sweden AB’s securities system who wishes to attend and vote at the Extraordinary General Meeting must:

This temporary registration upon written request to Euroclear Sweden AB counts as participation in the general meeting

A shareholder can attend the extraordinary general meeting and exercise his rights at the general meeting by proxy.A proxy must present a dated power of attorney or otherwise reliably prove his right to represent the shareholder at the extraordinary general meeting

If a shareholder takes part in the extraordinary general meeting with several proxies, who represent the shareholder with shares in different securities accounts, the shares with which each proxy represents the shareholder must be identified in connection with the registration for the shareholders Annual General Meeting

Any power of attorney documents should be delivered as originals to Nexstim Plc, “Extraordinary General Meeting” Elimäenkatu 9 B, 00510 Helsinki, Finland

before the last registration date

Pursuant to Chapter 5, Section 25 of the Companies Act, a shareholder who is present at the general meeting has the right to request information on matters under consideration at the general meeting

The meeting will be held in Finnish. Some of the material presented at the meeting may be in English

As of the date of this notification to the extraordinary general meeting of 8 February 2021, the total number of shares and votes in Nexstim Plc is 439622756

Nexstim is a Finnish, global medical technology company. Our mission is to provide personalized and effective therapies and diagnoses for challenging diseases and disorders of the brain

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®.It is a navigated transcranial magnetic stimulation (nTMS) technology with advanced 3D navigation that enables the TMS to be precisely and personalized to the specific area of ​​the brain

SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA approved for marketing and commercial sale for the treatment of Major Depression (MDD) in the United States the NBT® system CE-marked for the treatment of severe depression and chronic neuropathic pain

Nexstim also markets its SmartFocus®-based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE-marked navigated TMS system for preoperative mapping of speech and motor skills Cortices of the Brain Nexstim shares are listed on the Nasdaq First North Growth Market in Finland and the Nasdaq First North Growth Market in Sweden

Company announcement_invitation to EGM_FINAL_DE

Nexstim Oyj logo

Nexstim

World news – FI – Nexstim Plc: Invitation to the extraordinary general meeting

Source: https://www.globenewswire.com/news-release/2021/02/08/2171558/0/en/Nexstim-Plc-Invitation-to-the-Extraordinary-General-Meeting.html